Vanguard Specialized Funds · net assets $36.9B · 103 holdings as of April 30, 2026. Monthly N-PORT disclosure: the full book, not just equities.
EC: 98.7% · RA: 1.2% · STIV: 0.1%
| Month 1 | Month 2 | Month 3 | |
|---|---|---|---|
| Sales | $38.3M | $85.8M | $32.4M |
| Reinvestment | $0 | $1.27B | $6.02K |
| Redemptions | $327M | $405M | $421M |
| Net realized gain (non-derivative) | $430M | $203M | $513M |
| Net unrealized appreciation (non-derivative) | $737M | $-2.71B | $-512M |
The three months of the reporting period, as filed; month 3 ends April 30, 2026.
| Holding | Value | % of net assets |
|---|---|---|
| Eli Lilly & Co EC | $3.35B | 9.08% |
| Merck & Co Inc EC | $2B | 5.41% |
| Astrazeneca PLC EC | $1.88B | 5.09% |
| Unitedhealth Group Inc EC | $1.44B | 3.92% |
| Johnson & Johnson EC | $1.27B | 3.45% |
| Edwards Lifesciences Corp EC | $1.18B | 3.21% |
| Gsk PLC EC | $1.15B | 3.13% |
| Intuitive Surgical Inc EC | $1B | 2.71% |
| Boston Scientific Corp EC | $868M | 2.36% |
| Danaher Corp EC | $865M | 2.35% |
| Cvs Health Corp EC | $813M | 2.20% |
| Argenx Se EC | $813M | 2.20% |
| Abbott Laboratories EC | $803M | 2.18% |
| Vertex Pharmaceuticals Inc EC | $770M | 2.09% |
| Cencora Inc EC | $765M | 2.08% |
| Elevance Health Inc EC | $700M | 1.90% |
| Regeneron Pharmaceuticals Inc EC | $659M | 1.79% |
| Ucb Sa EC | $641M | 1.74% |
| Novartis Ag EC | $598M | 1.62% |
| Hca Healthcare Inc EC | $523M | 1.42% |
| Alnylam Pharmaceuticals Inc EC | $517M | 1.40% |
| Abbvie Inc EC | $498M | 1.35% |
| Biogen Inc EC | $478M | 1.30% |
| United Therapeutics Corp EC | $470M | 1.28% |
| Galderma Group Ag EC | $468M | 1.27% |
| Chugai Pharmaceutical Co Ltd EC | $459M | 1.25% |
| Roche Holding Ag EC | $457M | 1.24% |
| Otsuka Holdings Co Ltd EC | $452M | 1.23% |
| Cardinal Health Inc EC | $447M | 1.21% |
| Agilent Technologies Inc EC | $442M | 1.20% |
| Shionogi & Co Ltd EC | $413M | 1.12% |
| Dexcom Inc EC | $379M | 1.03% |
| Daiichi Sankyo Co Ltd EC | $368M | 1.00% |
| Thermo Fisher Scientific Inc EC | $357M | 0.97% |
| Genmab A/s EC | $356M | 0.97% |
| Medtronic PLC EC | $342M | 0.93% |
| Stryker Corp EC | $306M | 0.83% |
| Ionis Pharmaceuticals Inc EC | $284M | 0.77% |
| Revolution Medicines Inc EC | $265M | 0.72% |
| Ascendis Pharma A/s EC | $241M | 0.65% |
| Steris PLC EC | $237M | 0.64% |
| Incyte Corp EC | $225M | 0.61% |
| Qiagen Nv EC | $225M | 0.61% |
| Cytokinetics Inc EC | $223M | 0.60% |
| Bristol-myers Squibb Co EC | $222M | 0.60% |
| Eisai Co Ltd EC | $220M | 0.60% |
| Madrigal Pharmaceuticals Inc EC | $212M | 0.57% |
| Icon PLC EC | $182M | 0.49% |
| Novo Nordisk A/s EC | $176M | 0.48% |
| Cg Oncology Inc EC | $173M | 0.47% |
| Heartflow Inc EC | $169M | 0.46% |
| Avantor Inc EC | $166M | 0.45% |
| Scholar Rock Holding Corp EC | $162M | 0.44% |
| Encompass Health Corp EC | $160M | 0.43% |
| Vaxcyte Inc EC | $153M | 0.41% |
| Xenon Pharmaceuticals Inc EC | $150M | 0.41% |
| Kymera Therapeutics Inc EC | $146M | 0.40% |
| Alignment Healthcare Inc EC | $142M | 0.38% |
| Celldex Therapeutics Inc EC | $141M | 0.38% |
| Protagonist Therapeutics Inc EC | $137M | 0.37% |
Showing top 60 of 103 holdings.
Loading...
